Hummingbird Bioscience Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
83
- Latest Deal Type
-
2ndary - Private
- Investors
-
30
Hummingbird Bioscience General Information
Description
Developer of novel therapeutic antibody-based drugs designed to treat cancer and immuno-oncology patients. The company's drugs are developed based on a proprietary rational antibody discovery platform with deep experience in the application of integrative genomics and proteomics, enabling physicians to provide better treatments to cover the healthcare needs of patients that are not met by existing therapies.
Contact Information
Website
www.hummingbirdbioscience.comCorporate Office
- The Galen 61 Science Park Road
- Number 06-15/24
- Singapore, 117525
- Singapore
Corporate Office
- The Galen 61 Science Park Road
- Number 06-15/24
- Singapore, 117525
- Singapore
Hummingbird Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 8. Later Stage VC (Series C) | 15-Nov-2021 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 06-Nov-2020 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series B) | 11-May-2020 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A) | 01-Mar-2019 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 25-Feb-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | 01-Jul-2018 | Completed | Startup | |||
| 2. Early Stage VC | 03-May-2017 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
Hummingbird Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 11,548,952 | $0.81 | $0.81 | 1x | $0.81 | 10.19% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Hummingbird Bioscience Comparisons
Industry
Financing
Details
Hummingbird Bioscience Competitors (44)
One of Hummingbird Bioscience’s 44 competitors is Kymera Therapeutics, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| AUM Biosciences | Venture Capital-Backed | Singapore, Singapore | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany |
Hummingbird Bioscience Patents
Hummingbird Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026224308-A1 | Methods of treating cancer | Pending | 24-Apr-2025 | ||
| WO-2026221558-A1 | Antibody-drug conjugates | Pending | 16-Apr-2025 | ||
| WO-2026062200-A1 | B7-h3 antigen-binding molecules | Pending | 20-Sep-2024 | ||
| WO-2026063874-A1 | B7-h3 antigen-binding molecules | Pending | 20-Sep-2024 | ||
| WO-2026062072-A1 | Vista antigen-binding molecules | Pending | 18-Sep-2024 | C07K16/2827 |
Hummingbird Bioscience Signals
Hummingbird Bioscience Investors (30)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 5Y Capital | Venture Capital | Minority | ||
| Affinity Asset Advisors | Hedge Fund | Minority | ||
| Ally Bridge Group | Growth/Expansion | Minority | ||
| Altium Capital Management | Growth/Expansion | Minority | ||
| Amgen Ventures | Corporate Venture Capital | Minority |
Hummingbird Bioscience Investments (1)
Hummingbird Bioscience’s most recent deal was a Early Stage VC with Hillstar Bio for . The deal was made on 25-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hillstar Bio | 25-Mar-2025 | Early Stage VC | Drug Discovery |
Hummingbird Bioscience FAQs
-
When was Hummingbird Bioscience founded?
Hummingbird Bioscience was founded in 2015.
-
Where is Hummingbird Bioscience headquartered?
Hummingbird Bioscience is headquartered in Singapore, Singapore.
-
What is the size of Hummingbird Bioscience?
Hummingbird Bioscience has 83 total employees.
-
What industry is Hummingbird Bioscience in?
Hummingbird Bioscience’s primary industry is Drug Discovery.
-
Is Hummingbird Bioscience a private or public company?
Hummingbird Bioscience is a Private company.
-
What is Hummingbird Bioscience’s current revenue?
The current revenue for Hummingbird Bioscience is .
-
How much funding has Hummingbird Bioscience raised over time?
Hummingbird Bioscience has raised $162M.
-
Who are Hummingbird Bioscience’s investors?
5Y Capital, Affinity Asset Advisors, Ally Bridge Group, Altium Capital Management, and Amgen Ventures are 5 of 30 investors who have invested in Hummingbird Bioscience.
-
Who are Hummingbird Bioscience’s competitors?
Kymera Therapeutics, Centrose, Adaptimmune Therapeutics, AUM Biosciences, and TME Pharma are some of the 44 competitors of Hummingbird Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process